Studying safety and effectiveness of Poteligeo for certain skin lymphomas
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is tracking the safety and effectiveness of a drug called Poteligeo (mogamulizumab) for adults with mycosis fungoides or Sézary syndrome who have already tried at least one body-wide treatment. It is a post-market surveillance study, meaning the drug is already approved, and doctors are gathering real-world information about how well it works and any side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have a type of skin lymphoma called mycosis fungoides or Sézary syndrome.
- You have already tried at least one medicine that works throughout your body (systemic therapy) for this condition.
- You are not allergic to any of the ingredients in the study drug (mogamulizumab).
- You are not using the drug for a condition that is not approved.
- You have not received mogamulizumab in a previous clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether a combination of photopheresis and the drug mogamulizumab can improve outcomes in adults with advanced mycosis fungoides or Sézary syndrome, which are types of skin T-cell lymphoma. It may help by targeting lymphoma cells in the skin and immune system.
This trial tests a new drug called VG712 for people with a type of skin lymphoma called mycosis fungoides that has not responded to at least two previous treatments. The drug may help control the cancer, and the study will check if it is safe and effective.
This Phase 2 study tests mogamulizumab together with low-dose total skin electron beam radiation to treat mycosis fungoides or Sézary syndrome, two types of skin lymphoma. It may help shrink skin disease and control symptoms by combining an immune-targeting medicine with skin-focused radiation.
This study looks for “predictive” and “prognostic” biomarkers—measurable signs in blood or tissue—to help predict how mycosis fungoides or Sézary syndrome will behave and how patients may respond to care. It may help doctors better understand outcomes for people with these skin lymphomas.
This study tests a cream that targets inflammation in the skin for people with early-stage mycosis fungoides, a type of lymphoma. It may help relieve symptoms and slow the disease without stronger treatments.
This trial tests a gel form of a drug called duvelisib that you apply directly to skin lesions. It is for people with early-stage mycosis fungoides and may help control the patches without needing whole-body treatments.
Hear when a new Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.